Donga Pharmaceutical's Acne Scar Treatment 'Noscana Gel' Surpasses 60 Billion KRW in Cumulative Sales

Donga Pharmaceutical's Noscana Gel surpasses cumulative sales of 60 billion KRW.
[Photo by Donga Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Dong-A Pharmaceutical announced on the 18th that its acne scar treatment 'Noscana Gel,' which celebrated its 10th anniversary, has surpassed cumulative sales of 60 billion KRW.

Launched in 2013, Noscana Gel recorded sales of over 1 billion KRW in 2014 and achieved its first annual sales of 10 billion KRW in 2019. As of this day, cumulative sales amount to 62 billion KRW.

Noscana Gel has held the number one sales position in the acne scar treatment category (containing the same active ingredients: allantoin, dexpanthenol, heparin) from its launch to the present. Recently, with the full lifting of the outdoor mask mandate, the number of consumers wanting to cleanly manage scars left on their skin has increased, raising interest in Noscana Gel.

Noscana Gel is a scar treatment containing a triple complex of heparin sodium, allantoin, and dexpanthenol, which moisturizes the skin and regenerates scars. It is applied several times a day as needed to manage scars that could otherwise darken if left untreated. It is an over-the-counter drug available at pharmacies.

This content was produced with the assistance of AI translation services.